Lecanemab: Difference between revisions
| [pending revision] | [pending revision] |
Expand Lecanemab with Stahl-sourced detail (with skepticism) |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| Line 8: | Line 8: | ||
| fda_max = 10 mg/kg q2w | | fda_max = 10 mg/kg q2w | ||
| routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting | | routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting | ||
| onset = Slowing of cognitive decline over 18 months (modest effect | | onset = Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) | ||
| duration = Ongoing dosing | | duration = Ongoing dosing | ||
| halflife = ~5-7 days | | halflife = ~5-7 days | ||
| Line 16: | Line 16: | ||
| intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB. | | intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB. | ||
The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes | The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes, boxed warning recommends genotyping before treatment). Several deaths from ARIA-related cerebral edema/hemorrhage have been reported, particularly in patients on concurrent anticoagulants. | ||
The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree. | The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree. | ||
| pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement. | | pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement. | ||
| effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages) | | effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages), both often asymptomatic but can be serious. Infusion reactions. Headache. Boxed warning: APOE ε4 homozygotes at higher ARIA risk (~33% vs ~13% in non-carriers); genotype testing recommended before initiating. | ||
| interactions = <pharmaInteractions/> | | interactions = <pharmaInteractions/> | ||
}} | }} | ||
Revision as of 03:16, 19 May 2026
Anti-amyloid beta (Aβ) monoclonal antibody, targets protofibrils
Lecanemab
Leqembi
Lecanemab (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB.
Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement.
The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes, boxed warning recommends genotyping before treatment). Several deaths from ARIA-related cerebral edema/hemorrhage have been reported, particularly in patients on concurrent anticoagulants.
The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree.Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
ARIA-E (vasogenic edema) and ARIA-H (microhemorrhages), both often asymptomatic but can be serious. Infusion reactions. Headache. Boxed warning: APOE ε4 homozygotes at higher ARIA risk (~33% vs ~13% in non-carriers); genotype testing recommended before initiating.
Pharmacodynamics
Interactions
No interactions reported yet.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Anti-amyloid beta (Aβ) monoclonal antibody, targets protofibrils
Common uses
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023
Pharmacy
Starting dose
10 mg/kg IV every 2 weeks
Preparations
200 mg/2 mL, 500 mg/5 mL vials for IV infusion
US FDA Max
10 mg/kg q2w
Pharmacology
Routes
IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting
Onset
Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing)
Duration
Ongoing dosing
Half-life
~5-7 days
Bioavailability
100% (IV)
Pregnancy
Limited data
Legal status
Rx; REMS-like program for ARIA monitoring
Purported mechanism
Humanized IgG1 monoclonal antibody with higher affinity for soluble Aβ protofibrils than for monomeric Aβ or insoluble plaques. The protofibril-targeting rationale: soluble oligomers and protofibrils are hypothesized to be the most neurotoxic Aβ species. Promotes microglial clearance and reduces protofibril burden.